EP0477195A1 — Suramin type compounds and angiostatic steroids to inhibit angiogenesis
Assigned to Pharmacia and Upjohn Co · Expires 1992-04-01 · 34y expired
What this patent protects
The method described, which is used to treat angiogenesis in warm-blooded mammals in need of such treatment, comprises administering an angiogenesis-inhibiting amount of a combination consisting of a suramin-like compound and an angiostatic steroid. The angiostatic steroids are i…
USPTO Abstract
The method described, which is used to treat angiogenesis in warm-blooded mammals in need of such treatment, comprises administering an angiogenesis-inhibiting amount of a combination consisting of a suramin-like compound and an angiostatic steroid. The angiostatic steroids are in particular the steroids substituted in known position 20 of formula (I), the hydroxy steroids in position 21 of formula (II), the functionalized steroids in position C11 of formula (III) as well as the new DELTA9 esters (11) -etianics of formula (IV), as well as various known steroids taken separately.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.